|This article is part of MPR‘s coverage of IDWeek 2018, taking place in San Francisco, CA. Our on-site staff will be reporting on the latest breaking research and clinical advances in infectious diseases. Check back regularly for highlights from IDWeek 2018.|
SAN FRANCISCO — Treatment for hepatitis C (HCV) is associated with a reduction in cardiovascular events, according to results of a study presented at ID Week 2018 held October 3 to 7, 2018, in San Francisco, California.
Previous research has shown inconsistent results when evaluating the association between HCV and cardiovascular disease (CVD) and the effect of HCV treatment on the future risk for CVD developing. Researchers used the Electronically Retrieved Cohort of HCV Infected Veterans to identify individuals who had been treated for HCV for >7 weeks, and each of these patients was matched with an untreated person.
A total of 32,575 patients received treatment and were matched with an equal number of untreated patients. The median age was 58 years; 27% were black and a significant majority (96%) were male. The findings showed that the incidence rate for CVD events/1000 person-years in the treated group was 19.10 (95% CI, 17.79-20.50) vs an incidence of 32.37 (95% CI, 30.51-34.33) for the untreated cohort (P<.01). Treatment with a direct-acting antiretroviral regimen was associated with a lower risk for an incident CVD event compared to treatment with a peginterferon/ribavirin regimen (hazard ratio [HR] .68; 95% CI, .53-.88). This lower risk association was also demonstrated for achieving sustained virologic response (HR .76; 95% CI, .63-.92). Patients who were untreated also had a shorter CVD event-free survival during 30 months of follow-up compared to those who received treatment (log rank P<.0001).
|Visit MPR‘s conference section for continuous coverage live from IDWeek 2018.|
Butt, AA, Yan P, Shuaib A, Abou-Samra AB, Saikh O, Freiberg M. HCV treatment is associated with a reduced risk of cardiovascular disease events: results from ERCHIVES. Presented at: IDWeek 2018; October 3-7, 2018; San Francisco, CA. Abstract 930.
This article originally appeared on Infectious Disease Advisor